TY - JOUR
T1 - Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer
AU - Mustachio, Lisa Maria
AU - Lu, Yun
AU - Tafe, Laura J.
AU - Memoli, Vincent
AU - Rodriguez-Canales, Jaime
AU - Mino, Barbara
AU - Villalobos, Pamela Andrea
AU - Wistuba, Ignacio
AU - Katayama, Hiroyuki
AU - Hanash, Samir M.
AU - Roszik, Jason
AU - Kawakami, Masanori
AU - Cho, Kwang Jin
AU - Hancock, John F.
AU - Chinyengetere, Fadzai
AU - Hu, Shanhu
AU - Liu, Xi
AU - Freemantle, Sarah J.
AU - Dmitrovsky, Ethan
N1 - Publisher Copyright:
© 2017 AACR.
PY - 2017/7
Y1 - 2017/7
N2 - KRAS is frequently mutated in lung cancers and is associated with aggressive biology and chemotherapy resistance. Therefore, innovative approaches are needed to treat these lung cancers. Prior work implicated the IFN-stimulated gene 15 (ISG15) deubiquitinase (DUB) USP18 as having antineoplastic activity by regulating lung cancer growth and oncoprotein stability. This study demonstrates that USP18 affects the stability of the KRAS oncoprotein. Interestingly, loss of USP18 reduced KRAS expression, and engineered gain of USP18 expression increased KRAS protein levels in lung cancer cells. Using the protein synthesis inhibitor cycloheximide, USP18 knockdown significantly reduced the halflife of KRAS, but gain of USP18 expression significantly increased its stability. Intriguingly, loss of USP18 altered KRAS subcellular localization by mislocalizing KRAS from the plasma membrane. To explore the biologic consequences, immunohistochemical (IHC) expression profiles of USP18 were compared in lung cancers of KrasLA2/+ versus cyclin E engineered mouse models. USP18 expression was higher in Kras-driven murine lung cancers, indicating a link between KRAS and USP18 expression in vivo. To solidify this association, loss of Usp18 in KrasLA2/+/Usp18-/- mice was found to significantly reduce lung cancers as compared with parental KrasLA2/+ mice. Finally, translational relevance was confirmed in a human lung cancer panel by showing that USP18 IHC expression was significantly higher in KRAS-mutant versus wildtype lung adenocarcinomas.
AB - KRAS is frequently mutated in lung cancers and is associated with aggressive biology and chemotherapy resistance. Therefore, innovative approaches are needed to treat these lung cancers. Prior work implicated the IFN-stimulated gene 15 (ISG15) deubiquitinase (DUB) USP18 as having antineoplastic activity by regulating lung cancer growth and oncoprotein stability. This study demonstrates that USP18 affects the stability of the KRAS oncoprotein. Interestingly, loss of USP18 reduced KRAS expression, and engineered gain of USP18 expression increased KRAS protein levels in lung cancer cells. Using the protein synthesis inhibitor cycloheximide, USP18 knockdown significantly reduced the halflife of KRAS, but gain of USP18 expression significantly increased its stability. Intriguingly, loss of USP18 altered KRAS subcellular localization by mislocalizing KRAS from the plasma membrane. To explore the biologic consequences, immunohistochemical (IHC) expression profiles of USP18 were compared in lung cancers of KrasLA2/+ versus cyclin E engineered mouse models. USP18 expression was higher in Kras-driven murine lung cancers, indicating a link between KRAS and USP18 expression in vivo. To solidify this association, loss of Usp18 in KrasLA2/+/Usp18-/- mice was found to significantly reduce lung cancers as compared with parental KrasLA2/+ mice. Finally, translational relevance was confirmed in a human lung cancer panel by showing that USP18 IHC expression was significantly higher in KRAS-mutant versus wildtype lung adenocarcinomas.
UR - http://www.scopus.com/inward/record.url?scp=85021813126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021813126&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-16-0369
DO - 10.1158/1541-7786.MCR-16-0369
M3 - Article
C2 - 28242811
AN - SCOPUS:85021813126
SN - 1541-7786
VL - 15
SP - 905
EP - 914
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 7
ER -